schliessen

Filtern

 

Bibliotheken

Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study

Summary Background 90% of individuals infected with hepatitis C virus (HCV) worldwide reside in resource-limited settings. We aimed to characterise the prevalence of HCV, HIV/HCV co-infection, and the HCV care continuum in people who inject drugs in India. Methods 14 481 people (including 31 seeds—i... Full description

Journal Title: The Lancet infectious diseases 2015, Vol.15 (1), p.36-45
Main Author: Solomon, Sunil Suhas, Dr
Other Authors: Mehta, Shruti H, Prof , Srikrishnan, Aylur K, BA , Solomon, Suniti, Prof , McFall, Allison M, MHS , Laeyendecker, Oliver, PhD , Celentano, David D, Prof , Iqbal, Syed H, PhD , Anand, Santhanam, BSc , Vasudevan, Canjeevaram K, BSc , Saravanan, Shanmugam, PhD , Lucas, Gregory M, MD , Kumar, Muniratnam S, MD , Sulkowski, Mark S, Prof , Quinn, Thomas C, Prof
Format: Electronic Article Electronic Article
Language: English
Subjects:
HIV
Quelle: Alma/SFX Local Collection
Publisher: United States: Elsevier Ltd
ID: ISSN: 1473-3099
Link: https://www.ncbi.nlm.nih.gov/pubmed/25486851
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1654676428
title: Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
format: Article
creator:
  • Solomon, Sunil Suhas, Dr
  • Mehta, Shruti H, Prof
  • Srikrishnan, Aylur K, BA
  • Solomon, Suniti, Prof
  • McFall, Allison M, MHS
  • Laeyendecker, Oliver, PhD
  • Celentano, David D, Prof
  • Iqbal, Syed H, PhD
  • Anand, Santhanam, BSc
  • Vasudevan, Canjeevaram K, BSc
  • Saravanan, Shanmugam, PhD
  • Lucas, Gregory M, MD
  • Kumar, Muniratnam S, MD
  • Sulkowski, Mark S, Prof
  • Quinn, Thomas C, Prof
subjects:
  • Adolescent
  • Adult
  • Coinfection - epidemiology
  • Communicable Disease Control - methods
  • Cross-Sectional Studies
  • Developing Countries
  • Drug therapy
  • Drug use
  • Drugs
  • Female
  • Health aspects
  • Health Services Accessibility
  • Hepatitis
  • Hepatitis C - diagnosis
  • Hepatitis C - drug therapy
  • Hepatitis C - epidemiology
  • Hepatitis C Antibodies - blood
  • Hepatitis C virus
  • HIV
  • HIV Infections - complications
  • HIV Infections - epidemiology
  • Human immunodeficiency virus
  • Humans
  • India - epidemiology
  • Infectious Disease
  • Male
  • Prevalence
  • Substance Abuse, Intravenous - complications
  • Virus diseases
  • Young Adult
ispartof: The Lancet infectious diseases, 2015, Vol.15 (1), p.36-45
description: Summary Background 90% of individuals infected with hepatitis C virus (HCV) worldwide reside in resource-limited settings. We aimed to characterise the prevalence of HCV, HIV/HCV co-infection, and the HCV care continuum in people who inject drugs in India. Methods 14 481 people (including 31 seeds—individuals selected as the starting point for sampling because they were well connected in the drug using community) who inject drugs were sampled from 15 cities throughout India using respondent-driven sampling from Jan 2, 2013 to Dec 19, 2013. Data from seeds were excluded from all analyses. HCV prevalence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling weights. HCV care continuum outcomes were self-reported except for viral clearance in treatment-experienced participants. Findings The median age of participants was 30 years (IQR 24–36) and 13 608 (92·4%) of 14 449 were men (data were missing for some variables). Weighted HCV prevalence was 5777 (37·2%) of 14 447; HIV/HCV co-infection prevalence was 2085 (13·2%) of 14 435. Correlates of HCV infection included high lifetime injection frequency, HIV positivity, and a high prevalence of people with HIV RNA (more than 1000 copies per mL) in the community. Of the 5777 people who inject drugs that were HCV antibody positive, 440 (5·5%) were aware of their status, 225 (3·0%) had seen a doctor for their HCV, 79 (1·4%) had taken HCV treatment, and 18 (0·4%) had undetectable HCV RNA. Of 12 128 participants who had not previously been tested for HCV, 6138 (50·5%) did not get tested because they had not heard of HCV. In the 5777 people who were HCV antibody positive, 2086 (34·4%) reported harmful or hazardous alcohol use, of whom 1082 (50·4%) were dependent, and 3821 (65·3%) reported needle sharing. Awareness of HCV positive status was significantly associated with higher education, HIV testing history, awareness of HIV positive status, and higher community antiretroviral therapy coverage. Interpretation The high burden of HCV and HIV/HCV co-infection coupled with low-access to HCV services emphasises an urgent need to include resource-limited settings in the global HCV agenda. Although new treatments will become available worldwide in the near future, programmes to improve awareness and reduce disease progression and transmission need to be scaled up without further delay. Failure to do so could result in patterns of rising mortality, undermining advances in survival attribut
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1473-3099
fulltext: fulltext
issn:
  • 1473-3099
  • 1474-4457
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6165
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1654676428
sourceformatXML
sourcesystemPC
galeidA394820143
sourcerecordidA394820143
originalsourceidFETCH-LOGICAL-1633t-7755409964472408090f12d67907f1e18286e5434550f29d65b0b465d0a13a7f3
addsrcrecordideNqNkl9rFDEUxQdRbK1-BCXgSwWnJpM_M1NBqYt_CgUfVNi3kJ3c2U2dTdbcmZX9CH5rM7vV2qVQmYdMcn_nwOWcLHvK6AmjTL36wkTJc07r-piJFyWjQubTe9lheha5ELK8v_3fIQfZI8RLStnIPcwOCikqVUl2mP16N0QLnoSWLGBletc7JBOydnFAYh2CQSDGW2KaBhBJH27hEOLapTFxnqwgrDogPxch3S6h6YmNw3w7OvfWmVNiSBMDYo5p6II3HcF-sJvH2YPWdAhPrs6j7NuH918nn_KLzx_PJ2cXOVOc93lZSinSSkqIshC0ojVtWWFVWdOyZcCqolIgBRdS0raorZIzOhNKWmoYN2XLj7Ljne8qhh8DYK-XDhvoOuMhDKiZkkKVShTVf6CCqqouqEro8z30MgwxLTdSXBW0pJxdU3PTgXa-DX00zWiqz3gtqoIywRN1cguVPgtL1wQPrUvvNwQv_xHMBnQ-ZeU8uvmix7kZEG_icodvc4jQ6lV0SxM3mlE9lktvy6XH5mgm9LZcepp0z652HGZLsH9Vf9qUgNd7xo3rzRhyWsB1d9q_3akhpb92EDU2DnwD1sVUFW2Du9PhzZ5D0znvGtN9hw3gdSIaC013JqNHOkeHKf8NtbYCPg
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1636207031
display
typearticle
titleBurden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
sourceAlma/SFX Local Collection
creatorSolomon, Sunil Suhas, Dr ; Mehta, Shruti H, Prof ; Srikrishnan, Aylur K, BA ; Solomon, Suniti, Prof ; McFall, Allison M, MHS ; Laeyendecker, Oliver, PhD ; Celentano, David D, Prof ; Iqbal, Syed H, PhD ; Anand, Santhanam, BSc ; Vasudevan, Canjeevaram K, BSc ; Saravanan, Shanmugam, PhD ; Lucas, Gregory M, MD ; Kumar, Muniratnam S, MD ; Sulkowski, Mark S, Prof ; Quinn, Thomas C, Prof
creatorcontribSolomon, Sunil Suhas, Dr ; Mehta, Shruti H, Prof ; Srikrishnan, Aylur K, BA ; Solomon, Suniti, Prof ; McFall, Allison M, MHS ; Laeyendecker, Oliver, PhD ; Celentano, David D, Prof ; Iqbal, Syed H, PhD ; Anand, Santhanam, BSc ; Vasudevan, Canjeevaram K, BSc ; Saravanan, Shanmugam, PhD ; Lucas, Gregory M, MD ; Kumar, Muniratnam S, MD ; Sulkowski, Mark S, Prof ; Quinn, Thomas C, Prof
descriptionSummary Background 90% of individuals infected with hepatitis C virus (HCV) worldwide reside in resource-limited settings. We aimed to characterise the prevalence of HCV, HIV/HCV co-infection, and the HCV care continuum in people who inject drugs in India. Methods 14 481 people (including 31 seeds—individuals selected as the starting point for sampling because they were well connected in the drug using community) who inject drugs were sampled from 15 cities throughout India using respondent-driven sampling from Jan 2, 2013 to Dec 19, 2013. Data from seeds were excluded from all analyses. HCV prevalence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling weights. HCV care continuum outcomes were self-reported except for viral clearance in treatment-experienced participants. Findings The median age of participants was 30 years (IQR 24–36) and 13 608 (92·4%) of 14 449 were men (data were missing for some variables). Weighted HCV prevalence was 5777 (37·2%) of 14 447; HIV/HCV co-infection prevalence was 2085 (13·2%) of 14 435. Correlates of HCV infection included high lifetime injection frequency, HIV positivity, and a high prevalence of people with HIV RNA (more than 1000 copies per mL) in the community. Of the 5777 people who inject drugs that were HCV antibody positive, 440 (5·5%) were aware of their status, 225 (3·0%) had seen a doctor for their HCV, 79 (1·4%) had taken HCV treatment, and 18 (0·4%) had undetectable HCV RNA. Of 12 128 participants who had not previously been tested for HCV, 6138 (50·5%) did not get tested because they had not heard of HCV. In the 5777 people who were HCV antibody positive, 2086 (34·4%) reported harmful or hazardous alcohol use, of whom 1082 (50·4%) were dependent, and 3821 (65·3%) reported needle sharing. Awareness of HCV positive status was significantly associated with higher education, HIV testing history, awareness of HIV positive status, and higher community antiretroviral therapy coverage. Interpretation The high burden of HCV and HIV/HCV co-infection coupled with low-access to HCV services emphasises an urgent need to include resource-limited settings in the global HCV agenda. Although new treatments will become available worldwide in the near future, programmes to improve awareness and reduce disease progression and transmission need to be scaled up without further delay. Failure to do so could result in patterns of rising mortality, undermining advances in survival attributed to widespread HIV treatment. Funding US National Institutes of Health
identifier
0ISSN: 1473-3099
1EISSN: 1474-4457
2DOI: 10.1016/S1473-3099(14)71045-X
3PMID: 25486851
4CODEN: LANCAO
languageeng
publisherUnited States: Elsevier Ltd
subjectAdolescent ; Adult ; Coinfection - epidemiology ; Communicable Disease Control - methods ; Cross-Sectional Studies ; Developing Countries ; Drug therapy ; Drug use ; Drugs ; Female ; Health aspects ; Health Services Accessibility ; Hepatitis ; Hepatitis C - diagnosis ; Hepatitis C - drug therapy ; Hepatitis C - epidemiology ; Hepatitis C Antibodies - blood ; Hepatitis C virus ; HIV ; HIV Infections - complications ; HIV Infections - epidemiology ; Human immunodeficiency virus ; Humans ; India - epidemiology ; Infectious Disease ; Male ; Prevalence ; Substance Abuse, Intravenous - complications ; Virus diseases ; Young Adult
ispartofThe Lancet infectious diseases, 2015, Vol.15 (1), p.36-45
rights
0Elsevier Ltd
12015 Elsevier Ltd
2Copyright © 2015 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2015 Elsevier B.V.
4Copyright Elsevier Limited Jan 2015
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1633t-7755409964472408090f12d67907f1e18286e5434550f29d65b0b465d0a13a7f3
citesFETCH-LOGICAL-1633t-7755409964472408090f12d67907f1e18286e5434550f29d65b0b465d0a13a7f3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25486851$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Solomon, Sunil Suhas, Dr
1Mehta, Shruti H, Prof
2Srikrishnan, Aylur K, BA
3Solomon, Suniti, Prof
4McFall, Allison M, MHS
5Laeyendecker, Oliver, PhD
6Celentano, David D, Prof
7Iqbal, Syed H, PhD
8Anand, Santhanam, BSc
9Vasudevan, Canjeevaram K, BSc
10Saravanan, Shanmugam, PhD
11Lucas, Gregory M, MD
12Kumar, Muniratnam S, MD
13Sulkowski, Mark S, Prof
14Quinn, Thomas C, Prof
title
0Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
1The Lancet infectious diseases
addtitleLancet Infect Dis
descriptionSummary Background 90% of individuals infected with hepatitis C virus (HCV) worldwide reside in resource-limited settings. We aimed to characterise the prevalence of HCV, HIV/HCV co-infection, and the HCV care continuum in people who inject drugs in India. Methods 14 481 people (including 31 seeds—individuals selected as the starting point for sampling because they were well connected in the drug using community) who inject drugs were sampled from 15 cities throughout India using respondent-driven sampling from Jan 2, 2013 to Dec 19, 2013. Data from seeds were excluded from all analyses. HCV prevalence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling weights. HCV care continuum outcomes were self-reported except for viral clearance in treatment-experienced participants. Findings The median age of participants was 30 years (IQR 24–36) and 13 608 (92·4%) of 14 449 were men (data were missing for some variables). Weighted HCV prevalence was 5777 (37·2%) of 14 447; HIV/HCV co-infection prevalence was 2085 (13·2%) of 14 435. Correlates of HCV infection included high lifetime injection frequency, HIV positivity, and a high prevalence of people with HIV RNA (more than 1000 copies per mL) in the community. Of the 5777 people who inject drugs that were HCV antibody positive, 440 (5·5%) were aware of their status, 225 (3·0%) had seen a doctor for their HCV, 79 (1·4%) had taken HCV treatment, and 18 (0·4%) had undetectable HCV RNA. Of 12 128 participants who had not previously been tested for HCV, 6138 (50·5%) did not get tested because they had not heard of HCV. In the 5777 people who were HCV antibody positive, 2086 (34·4%) reported harmful or hazardous alcohol use, of whom 1082 (50·4%) were dependent, and 3821 (65·3%) reported needle sharing. Awareness of HCV positive status was significantly associated with higher education, HIV testing history, awareness of HIV positive status, and higher community antiretroviral therapy coverage. Interpretation The high burden of HCV and HIV/HCV co-infection coupled with low-access to HCV services emphasises an urgent need to include resource-limited settings in the global HCV agenda. Although new treatments will become available worldwide in the near future, programmes to improve awareness and reduce disease progression and transmission need to be scaled up without further delay. Failure to do so could result in patterns of rising mortality, undermining advances in survival attributed to widespread HIV treatment. Funding US National Institutes of Health
subject
0Adolescent
1Adult
2Coinfection - epidemiology
3Communicable Disease Control - methods
4Cross-Sectional Studies
5Developing Countries
6Drug therapy
7Drug use
8Drugs
9Female
10Health aspects
11Health Services Accessibility
12Hepatitis
13Hepatitis C - diagnosis
14Hepatitis C - drug therapy
15Hepatitis C - epidemiology
16Hepatitis C Antibodies - blood
17Hepatitis C virus
18HIV
19HIV Infections - complications
20HIV Infections - epidemiology
21Human immunodeficiency virus
22Humans
23India - epidemiology
24Infectious Disease
25Male
26Prevalence
27Substance Abuse, Intravenous - complications
28Virus diseases
29Young Adult
issn
01473-3099
11474-4457
fulltexttrue
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqNkl9rFDEUxQdRbK1-BCXgSwWnJpM_M1NBqYt_CgUfVNi3kJ3c2U2dTdbcmZX9CH5rM7vV2qVQmYdMcn_nwOWcLHvK6AmjTL36wkTJc07r-piJFyWjQubTe9lheha5ELK8v_3fIQfZI8RLStnIPcwOCikqVUl2mP16N0QLnoSWLGBletc7JBOydnFAYh2CQSDGW2KaBhBJH27hEOLapTFxnqwgrDogPxch3S6h6YmNw3w7OvfWmVNiSBMDYo5p6II3HcF-sJvH2YPWdAhPrs6j7NuH918nn_KLzx_PJ2cXOVOc93lZSinSSkqIshC0ojVtWWFVWdOyZcCqolIgBRdS0raorZIzOhNKWmoYN2XLj7Ljne8qhh8DYK-XDhvoOuMhDKiZkkKVShTVf6CCqqouqEro8z30MgwxLTdSXBW0pJxdU3PTgXa-DX00zWiqz3gtqoIywRN1cguVPgtL1wQPrUvvNwQv_xHMBnQ-ZeU8uvmix7kZEG_icodvc4jQ6lV0SxM3mlE9lktvy6XH5mgm9LZcepp0z652HGZLsH9Vf9qUgNd7xo3rzRhyWsB1d9q_3akhpb92EDU2DnwD1sVUFW2Du9PhzZ5D0znvGtN9hw3gdSIaC013JqNHOkeHKf8NtbYCPg
startdate2015
enddate2015
creator
0Solomon, Sunil Suhas, Dr
1Mehta, Shruti H, Prof
2Srikrishnan, Aylur K, BA
3Solomon, Suniti, Prof
4McFall, Allison M, MHS
5Laeyendecker, Oliver, PhD
6Celentano, David D, Prof
7Iqbal, Syed H, PhD
8Anand, Santhanam, BSc
9Vasudevan, Canjeevaram K, BSc
10Saravanan, Shanmugam, PhD
11Lucas, Gregory M, MD
12Kumar, Muniratnam S, MD
13Sulkowski, Mark S, Prof
14Quinn, Thomas C, Prof
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
90TZ
103V.
117QL
127RV
137U9
147X7
157XB
1688E
178AO
188C1
198C2
208FI
218FJ
228FK
23ABUWG
24BENPR
25C1K
26FYUFA
27GHDGH
28H94
29K9.
30KB0
31M0S
32M1P
33M7N
34NAPCQ
35PQEST
36PQQKQ
37PQUKI
387X8
sort
creationdate2015
titleBurden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
authorSolomon, Sunil Suhas, Dr ; Mehta, Shruti H, Prof ; Srikrishnan, Aylur K, BA ; Solomon, Suniti, Prof ; McFall, Allison M, MHS ; Laeyendecker, Oliver, PhD ; Celentano, David D, Prof ; Iqbal, Syed H, PhD ; Anand, Santhanam, BSc ; Vasudevan, Canjeevaram K, BSc ; Saravanan, Shanmugam, PhD ; Lucas, Gregory M, MD ; Kumar, Muniratnam S, MD ; Sulkowski, Mark S, Prof ; Quinn, Thomas C, Prof
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1633t-7755409964472408090f12d67907f1e18286e5434550f29d65b0b465d0a13a7f3
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
0Adolescent
1Adult
2Coinfection - epidemiology
3Communicable Disease Control - methods
4Cross-Sectional Studies
5Developing Countries
6Drug therapy
7Drug use
8Drugs
9Female
10Health aspects
11Health Services Accessibility
12Hepatitis
13Hepatitis C - diagnosis
14Hepatitis C - drug therapy
15Hepatitis C - epidemiology
16Hepatitis C Antibodies - blood
17Hepatitis C virus
18HIV
19HIV Infections - complications
20HIV Infections - epidemiology
21Human immunodeficiency virus
22Humans
23India - epidemiology
24Infectious Disease
25Male
26Prevalence
27Substance Abuse, Intravenous - complications
28Virus diseases
29Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Solomon, Sunil Suhas, Dr
1Mehta, Shruti H, Prof
2Srikrishnan, Aylur K, BA
3Solomon, Suniti, Prof
4McFall, Allison M, MHS
5Laeyendecker, Oliver, PhD
6Celentano, David D, Prof
7Iqbal, Syed H, PhD
8Anand, Santhanam, BSc
9Vasudevan, Canjeevaram K, BSc
10Saravanan, Shanmugam, PhD
11Lucas, Gregory M, MD
12Kumar, Muniratnam S, MD
13Sulkowski, Mark S, Prof
14Quinn, Thomas C, Prof
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8Pharma and Biotech Premium PRO
9ProQuest Central (Corporate)
10Bacteriology Abstracts (Microbiology B)
11Nursing & Allied Health Database
12Virology and AIDS Abstracts
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Medical Database (Alumni Edition)
16ProQuest Pharma Collection
17Public Health Database
18Lancet Titles
19Hospital Premium Collection
20Hospital Premium Collection (Alumni Edition)
21ProQuest Central (Alumni) (purchase pre-March 2016)
22ProQuest Central (Alumni Edition)
23ProQuest Central
24Environmental Sciences and Pollution Management
25Health Research Premium Collection
26Health Research Premium Collection (Alumni)
27AIDS and Cancer Research Abstracts
28ProQuest Health & Medical Complete (Alumni)
29Nursing & Allied Health Database (Alumni Edition)
30Health & Medical Collection (Alumni Edition)
31Medical Database
32Algology Mycology and Protozoology Abstracts (Microbiology C)
33Nursing & Allied Health Premium
34ProQuest One Academic Eastern Edition
35ProQuest One Academic
36ProQuest One Academic UKI Edition
37MEDLINE - Academic
jtitleThe Lancet infectious diseases
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Solomon, Sunil Suhas, Dr
1Mehta, Shruti H, Prof
2Srikrishnan, Aylur K, BA
3Solomon, Suniti, Prof
4McFall, Allison M, MHS
5Laeyendecker, Oliver, PhD
6Celentano, David D, Prof
7Iqbal, Syed H, PhD
8Anand, Santhanam, BSc
9Vasudevan, Canjeevaram K, BSc
10Saravanan, Shanmugam, PhD
11Lucas, Gregory M, MD
12Kumar, Muniratnam S, MD
13Sulkowski, Mark S, Prof
14Quinn, Thomas C, Prof
formatjournal
genrearticle
ristypeJOUR
atitleBurden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
jtitleThe Lancet infectious diseases
addtitleLancet Infect Dis
date2015
risdate2015
volume15
issue1
spage36
epage45
pages36-45
issn1473-3099
eissn1474-4457
codenLANCAO
abstractSummary Background 90% of individuals infected with hepatitis C virus (HCV) worldwide reside in resource-limited settings. We aimed to characterise the prevalence of HCV, HIV/HCV co-infection, and the HCV care continuum in people who inject drugs in India. Methods 14 481 people (including 31 seeds—individuals selected as the starting point for sampling because they were well connected in the drug using community) who inject drugs were sampled from 15 cities throughout India using respondent-driven sampling from Jan 2, 2013 to Dec 19, 2013. Data from seeds were excluded from all analyses. HCV prevalence was estimated by the presence of anti-HCV antibodies incorporating respondent-driven sampling weights. HCV care continuum outcomes were self-reported except for viral clearance in treatment-experienced participants. Findings The median age of participants was 30 years (IQR 24–36) and 13 608 (92·4%) of 14 449 were men (data were missing for some variables). Weighted HCV prevalence was 5777 (37·2%) of 14 447; HIV/HCV co-infection prevalence was 2085 (13·2%) of 14 435. Correlates of HCV infection included high lifetime injection frequency, HIV positivity, and a high prevalence of people with HIV RNA (more than 1000 copies per mL) in the community. Of the 5777 people who inject drugs that were HCV antibody positive, 440 (5·5%) were aware of their status, 225 (3·0%) had seen a doctor for their HCV, 79 (1·4%) had taken HCV treatment, and 18 (0·4%) had undetectable HCV RNA. Of 12 128 participants who had not previously been tested for HCV, 6138 (50·5%) did not get tested because they had not heard of HCV. In the 5777 people who were HCV antibody positive, 2086 (34·4%) reported harmful or hazardous alcohol use, of whom 1082 (50·4%) were dependent, and 3821 (65·3%) reported needle sharing. Awareness of HCV positive status was significantly associated with higher education, HIV testing history, awareness of HIV positive status, and higher community antiretroviral therapy coverage. Interpretation The high burden of HCV and HIV/HCV co-infection coupled with low-access to HCV services emphasises an urgent need to include resource-limited settings in the global HCV agenda. Although new treatments will become available worldwide in the near future, programmes to improve awareness and reduce disease progression and transmission need to be scaled up without further delay. Failure to do so could result in patterns of rising mortality, undermining advances in survival attributed to widespread HIV treatment. Funding US National Institutes of Health
copUnited States
pubElsevier Ltd
pmid25486851
doi10.1016/S1473-3099(14)71045-X
oafree_for_read